Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Imagine ... all the possibilities

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Mar 07, 2021 12:28pm

136 Views

Post# 32738803

RE:Imagine ... all the possibilities

Welcome to pumper town. I will be happy when the stock price moves and holds. Over the last 12 months it has done little, and when it has, the CEO has crushed it.

I've read all the articles, and the science. Heard all the excuses, saw all the bait and switches from "mature company's always file a prospectus, doesn't mean we will engage in that" or "we are looking at a NASDQ uplisting and things could move fast in January." I feel a lil burned by the biz side of this. Still holding and keeping my fingers crossed. Hopefully there is a release and positive news to get some movement again.

<< Previous

Bullboard Posts

Next >>

Cybeats expands to Belgium with Capyx commercial partnership